GLP-1s, Pregnancy and Trying to Conceive: What the Labels Say

If you are pregnant, or there is any chance you might be, tell a clinician this week and bring the name of the drug with you. Nothing that follows is a substitute for that. What follows sets out what the five approved labels say about pregnancy, about the interval before a planned one, and about breastfeeding, so that the conversation starts from the same text your prescriber is working from. We read all five on August 15, 2026.

The interval before a planned pregnancy, drug by drug

This is the fact most readers come for, and it differs across the class. All three semaglutide labels name a period. Neither tirzepatide label names one.

Where the two months comes from

The labels tie the interval explicitly to how long the drug lingers. Semaglutide takes about a week to fall by half, and the Ozempic label says the drug is still circulating roughly five weeks after a last dose.^[2] Wegovy's clinical pharmacology section stretches that to five to seven weeks at its higher strengths.^[1] Two months is that tail plus a margin.

Tirzepatide clears faster. Its labels put the elimination half-life at approximately five days, and Zepbound's at five to six days in people with overweight or obesity.^[4][5] A shorter tail is a plausible reason for a shorter interval. It is not a reason to assume none, and neither Lilly label converts it into one. Our account of where the tirzepatide evidence stops draws a similar line elsewhere in the label, between a warning and a counted rate.

What the animal studies found

Every one of the five labels rests its pregnancy caution on animal reproduction data, and every one is candid that the human data are insufficient.

• Semaglutide in rats: embryofetal death, structural abnormalities and altered growth, at maternal exposures no higher than the ceiling of the human dose range.^[2]
• Semaglutide in rabbits and cynomolgus monkeys: early pregnancy losses and structural abnormalities, at clinically relevant exposures in rabbits.^[1][2]
• Tirzepatide in rats: external, visceral and skeletal malformations and reduced fetal weights at the highest dose given during organogenesis.^[5]
• Tirzepatide in rabbits: a few animals died or aborted, at every dose level tested, and fetal weights fell at the top dose.^[5]
• SNAC, the absorption enhancer in the semaglutide tablets, crosses the placenta in rats; a rat study reported longer gestation, more stillbirths and lower pup viability.^[3]

Both manufacturers add the same qualification, and it matters. In the animals, these effects coincided with marked maternal weight loss and reduced food intake, which is what the drugs are designed to do to the mother. That does not make the findings irrelevant, but the effects may be downstream of reduced maternal intake rather than direct toxicity, and neither label claims to know which.^[1][5]

What the human record shows so far

Two 2026 analyses are the largest available, and neither settles the question.

The first emulated a trial inside U.S. insurance claims covering 2011 to 2024, comparing 3,572 pregnancies in women who had a GLP-1 prescription filled in the 90 days before their last menstrual period, split by whether they filled another one during the first trimester. Nonlive birth occurred in 29.7% of the continuation group against 27.1% of the noncontinuation group, an adjusted risk ratio of 1.09. Prevalence ratios were 1.29 for small-for-gestational-age, 1.08 for large-for-gestational-age and 1.21 for major congenital malformation. In the authors' conclusion, risks were not definitively higher, but the malformation and growth estimates were imprecise and compatible with both no increased risk and a clinically relevant one.^[6]

The second pooled 22 studies covering 49,395 pregnancies with exposure around conception. It found no statistically significant association with major congenital malformations, cardiac malformations, gestational age or weight, preterm delivery, live birth, pregnancy loss, hypertensive disorders or cesarean delivery. One signal did reach significance: renal malformations, at an odds ratio of 1.23, which the authors attribute largely to a single large cohort with substantial baseline imbalances.^[7]

Read together, they say a large and obvious signal has not appeared in what has been collected so far. They do not say these drugs are safe in pregnancy, and no label treats them as such. The evidence base is thin, and it is not reassuring just because it has been read carefully.

A smaller 2026 systematic review (five studies, 1,128 exposed pregnancies) adds one observation the larger analyses above do not make, and it runs against a common assumption. One of its included studies linked semaglutide discontinuation to fetal macrosomia and neonatal hypoglycemia.^[11]

The same review is a useful caution about reading single figures. One of its studies reported congenital malformations in 8.3% of exposed pregnancies and another a 23% rate of spontaneous abortion. Those numbers are frightening alone, and each was reported alongside a comparison that changes them: no significant increase against insulin in the first case, and comparable to the diabetes and obesity groups in the second. Diabetes and obesity each raise these risks independently, so the comparison has to be against other women with those conditions. Set against healthy pregnancies, the disease gets credited to the drug.^[11]

The largest synthesis so far, and one number on breastfeeding

A 2026 systematic review searched four databases and pulled together 36 studies of exposure before conception, during pregnancy, or while breastfeeding, substantially more than anything above.^[12] Its conclusion is consistent with them and stated more firmly: periconceptional or early-pregnancy exposure was not consistently associated with increased major congenital malformations in adjusted analyses, nor with fetal growth restriction, stillbirth or neonatal mortality, compared with insulin-treated or disease-matched controls.

Maternal outcomes (gestational diabetes, hypertensive disorders, preterm birth, gestational weight gain) came out heterogeneous, with no reproducible signal in either direction.

That is one study, and “no detectable” always means below the limit of whatever assay was used rather than absent. It still points the reassuring way, on a question a great many women ask and the injectable labels leave unanswered.

Losing weight during a pregnancy is not the goal

The obesity labels are unusually blunt. Wegovy's risk summary states that there is no benefit to a pregnant patient in losing weight and that it may harm the fetus, and it directs prescribers to stop the drug for anyone taking it to reduce weight once a pregnancy has been identified.^[1] Zepbound opens its own risk summary with the same sentence.^[4]

Both then point at the reason. Guidance still calls for weight to be gained during pregnancy, in an amount set by the weight someone started at, and that holds for people who already have overweight or obesity, because maternal tissue itself adds weight.^[1][4] Whatever case there was for treatment before conception, the target changes.

Wegovy is the one exception the label carves out, and it is narrow: for the liver indication, where the untreated condition carries its own risks to mother and fetus, the label permits treatment during pregnancy only where the likely benefit outweighs the possible risk, and states that whether it reduces those risks is unknown.^[1]

Breastfeeding: the labels split by formulation

This is where the answer stops tracking the molecule and starts tracking what else is in the product. The full lactation picture, drug by drug, including Foundayo, Saxenda and LactMed’s summaries, is in GLP-1s while breastfeeding. If you are choosing a seller after a birth, our postpartum board puts these label limits ahead of its list.

• The semaglutide tablets (Rybelsus, Ozempic tablets and Wegovy tablets) advise that breastfeeding is not recommended during treatment. Semaglutide itself was below the limit of quantification in human milk; the concern is SNAC and its metabolites, which are present in milk, and which infants may clear more slowly than adults.^[1][3]
• Injectable semaglutide carries no such advice. Wegovy injection and Ozempic have no human milk data at all, and both fall back on the standard formula: set the health and developmental value of breastfeeding against how much the mother needs the drug.^[1][2]
• Tirzepatide has a lactation study behind it. After a single 5 mg study dose given to 11 lactating women, tirzepatide was undetectable in 164 of 171 milk samples; across the 7 that were measurable, the cumulative amount over 28 days came to under 0.02% of the dose the mother received. There are still no data on effects on a breastfed infant or on milk production, and both labels use the same weighing exercise.^[4][5]

Fertility can come back before the plan does

This is the practical point most likely to matter, and it is the one least likely to be raised in an appointment. Losing a meaningful amount of weight can restore ovulation in people who were not ovulating reliably, particularly with polycystic ovary syndrome, and menstrual cycles that had been irregular can become regular. Reviews of the reproductive evidence describe exactly that: ovulatory function improving and conception becoming likelier, arriving alongside a human safety record in early pregnancy that is still small and heterogeneous.^[8][9] The trial evidence on conception itself is thin: a systematic review of weight-lowering drugs and natural fertility found one GLP-1 trial, in 80 women.

The sequence that catches people off guard is not carelessness. Someone starts treatment while subfertile, contraception is either absent or was never a live concern, fertility improves faster than the plan around it, and a pregnancy begins during treatment. If you have been told conceiving would be difficult, treat that assessment as out of date once the weight starts moving, and settle the contraception question before it becomes retrospective. The labeled contraceptive interaction is a separate issue and it points the same way.

That matters most where PCOS is the reason for treatment. PCOS Sisters, a nurse-practitioner clinic built around PCOS, includes unlimited video visits in its membership, which leaves room to raise contraception before it becomes urgent.

The pregnancy registries

Two of the five labels ask for something back. Novo Nordisk runs a pregnancy exposure registry for Wegovy, reachable on 1-877-390-2760 or at wegovypregnancyregistry.com.^[1] The Zepbound label states that a registry will monitor outcomes in women exposed during pregnancy and directs patients and clinicians to Eli Lilly on 1-800-LillyRx.^[4] Ozempic, the semaglutide tablets and Mounjaro carry no registry text.

Enrolling is voluntary and it does nothing for your own pregnancy. It is how the evidence base above stops being thin, and right now it is thin because the exposures that have happened were mostly never recorded.

Questions worth taking to the appointment

1. Which drug am I on, and which label applies to me? The pre-pregnancy interval exists for semaglutide and not for tirzepatide, so the name decides the conversation.
2. Why am I taking it? Diabetes, weight, cardiovascular risk and liver disease are different indications, and the labels weigh pregnancy against each differently.
3. If I want to conceive, what is the plan and what replaces the treatment? Stopping is not a standalone decision, particularly with diabetes, where the labels are explicit that poorly controlled disease carries its own risks in pregnancy.
4. If I am already pregnant, what happens now? Ask about the registry at the same time.
5. If I am breastfeeding, does the formulation change the answer? For the tablets, the labels say it does.
6. Is my contraception adequate for the drug I am on? Ask it even if you are not planning a pregnancy.

If you buy through one of the telehealth programs aimed at women, the first question is easier to answer when the seller names its pharmacy. Tell Her Doc lists Belmar, Strive, Epiq Scripts and Casa Pharma Rx as the pharmacies that may fill an order, and PCOS Sisters names Strive and Striker. Sommar Club names its compounding pharmacy and its physician group. The same check works on a general seller: Rese Wellness, which serves both women and men, names its pharmacy in its FAQ.

Others leave a gap you will need to fill yourself. SexyMD names its prescribing entities in its terms but no pharmacy, and Alinwell names neither its pharmacy nor its medical group. Ambiante Health & Wellness connects patients with independent providers and quotes its price only after a provider review, which is a natural point to ask the questions above. Fitstry, aimed at women over 40, advertises visits, coaching and a lab panel as included for a limited time; a visit you are not paying extra for is a good place to ask them.